Dr Bharat Daftary (CMD)
R&D, manufacturing and marketing of biological, pharmaceutical and biotechnology products
Hoechst House, 16th Floor, Nariman Point, Mumbai-400021, Maharashtra
Fiscal 2009-10 saw Bharat Serums and Vaccines (BSV) registering a growth of 25 per cent clocking a total
sales turnover of Rs 175 crore as against Rs 140 crore in fiscal 2008-09. The BSV registered a good
growth as against the industry growth of 16 percent in 2009.
BSV has received funding from the Malaysian firm OrbiMed to fecilitate the next stage of growth.
“Investment in BSV by one of the largest healthcare focused funds validates our company's research,
manufacturing and marketing capabilities and distinctive business model. OrbiMed's investment and
involvement will considerably facilitate the next stage of BSV's growth,” stated Bharat Daftary,
chairman and managing director of BSV.
“BSV continues to be at the forefront of proprietary research of value added therapeutics and the
investment by a knowledgeable investor like OrbiMed acts a booster for our self belief, long term
value generation and growth prospects,” Dr Daftary added.
The company manufactures and markets biological, pharmaceutical and biotechnology products and has in
its portfolio over 25 brands which includes Plasma Derivatives, Monoclonals, Equine Antitoxins And
Serums, Cardiovascular, Antimicrobials, Antifungals, Anesthetics, Hormones. Over the years, BSV has
put in emphasis on its R&D operations both in India and overseas. It has three distinct R&D divisions
working extensively on NDDS, biotechnology and equine products.
In April 2010, Piramal Healthcare Limited, acquired BSV's injectible anesthetic products business.
The former signed a definitive agreement to acquire the Pune-based Bharat Serum's injectible anaesthetic
products business including – propofol, bupivacaine and atracurium besylate.
BSV holds a significant market share in India for plasma derivatives. The product portfolio comprises
a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums,
antifungals, anaesthetics, cardiovascular and diagnostic products.
BSV has allocated substantial resources towards the research and development of pharmaceutical products
in the areas of Novel Drug Delivery, Biotechnology and Biologicals. BSV has a pipeline of novel products
and “difficult generics” and is in discussions with potential partners for commercialization of these
The novel products include certain New Biological Entities and Novel Drug Delivery systems. The patents
for these products will belong to BSV.
The anti-infective product is from the drug delivery research and comes under the category of difficult
generics. BSV is seeking various partnering models including licensing, co-development, to commercialize